Pharma lobbyists focus on a surprising new target: the FDA
statnews.com • • business
Key Points:
- Health Secretary Robert F. Kennedy Jr. has pledged to eliminate industry influence within the Food and Drug Administration (FDA).
- Despite these promises, the Trump administration's infusion of political priorities into the FDA has increased opportunities for pharmaceutical industry lobbying.
- Sources including lobbyists, advisers, and FDA officials indicate that the nature of interactions between the pharmaceutical industry and the FDA has fundamentally changed under Trump.
- Michael Abrams, a consultant for pharmaceutical clients, noted that discussions about FDA decisions that were previously taboo have become commonplace in the current administration.
